Editorials

Rheumatoid Arthritis Clinical Benefits from Abatacept, Cytokine Blockers, and Rituximab Are All Linked to Modulation of Memory B Cell Responses
G.J. Silverman, A. Pelzek ........................................ 825

Growing Up and Moving On — Transition of Care for Patients with Childhood-onset Rheumatic Disease
A. Hersh ................................................................. 829

Radiography Versus Magnetic Resonance Imaging (MRI) in Juvenile Spondyloarthritis: Is the MR Image Everything?
P.F. Weiss, R.A. Colbert ............................................. 832

The Current and Future Status of Biomarkers in Osteoarthritis
D. Felson ................................................................. 834

Articles

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of RA in Open-label, Longterm Extension Studies

Are Baseline High Molecular Weight Adiponectin Levels Associated with Radiographic Progression in RA and OA?

Late-onset Neutropenia in Patients with RA after Treatment with Rituximab

Recent Trends in Orthopedic Surgery Aiming to Improve Quality of Life for Those with RA: Data from a Large Observational Cohort
S. Momohara, E. Inoue, K. Ikari, et al ......................... 862

Arthroplasty Rates Are Increased Among US Patients with SLE: 1991–2005
C. Mertelsmann-Voss, S. Lyman, T.J. Pan, S. Goodman, M.P. Figgie, L.A. Mandl ........................................ 867

ACR Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort

Effect of Hydroxychloroquine on the Lipid Profile of Patients with Sjögren Syndrome
E. Markatseli, C. Iliou, P.V. Voulgari, A.A. Drosos .......... 902

Increased Risks of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren Syndrome: A Nationwide Cohort Study
Y. Cao, Z. Tian, W. Li, L. Ma, Y. Yu, W. Ren .............. 916

Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis
P.C. Grayson, N.A. Amudala, C.A. McAlear, et al .......... 923

Potential Role of Hyaluronic Acid on Bone in OA: Matrix Metalloproteinases, Aggrecanases, and RANKL Expression are Partially Prevented by Hyaluronic Acid in Interleukin 1β–stimulated Osteoblasts
Z. Madenovic, A-S. Saurel, F. Berenbaum, C. Jacques ...................................................... 945

Effect of Urate-lowering Therapies on Renal Disease Progression in Patients with Hyperuricemia
G.D. Levy, N. Rashid, F. Niu, T.C. Cheetham ................ 955

Contents continued on page lviii
Pediatric Rheumatology
Diagnostic Utility of MRI and Radiography in Juvenile Spondyloarthritis: Evaluation of the Sacroiliac Joints in Controls and Affected Subjects
J.L. Jaremko, L. Liu, N.J. Winn, J.E. Ellsworth, R.G.W. Lambert .......................................................... 963

Images in Rheumatology
Optical Coherence Tomographic Imaging in a Patient with Granulomatosis with Polyangiitis Presenting with Acute Myocardial Infarction
D.Z.L. Khoo, E. Lee, P.J.L. Ong, H.H. Ho ........................................ 971
Spacing of Toes Reveals Rheumatoid Nodulosis
C. Prati, B.B. Brion, G. Leclerc, D. Wendling ...................... 973

OMERACT 11
The OMERACT Filter 2.0
Updating the OMERACT Filter at OMERACT 11
J.R. Kirwan, M. Boers, P. Tugwell ........................................ 975
Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11
M. Boers, L. Idzerda, J.R. Kirwan, et al .......................... 978
Can We Decide Which Outcomes Should Be Measured in Every Clinical Trial? A Scoping Review of the Existing Conceptual Frameworks and Processes to Develop Core Outcome Sets
L. Idzerda, T. Rader, P. Tugwell, M. Boers .................. 986
Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets
Updating the OMERACT Filter: Implications of Filter 2.0 to Select Outcome Instruments Through Assessment of “Truth”: Content, Face, and Construct Validity
Updating the OMERACT Filter: Discrimination and Feasibility
Updating the OMERACT Filter: Implications for Patient-reported Outcomes
Updating the OMERACT Filter: Implications for Imaging and Soluble Biomarkers
How to Choose Core Outcome Measurement Sets for Clinical Trials: OMERACT 11 Approves Filter 2.0
M. Boers, J.R. Kirwan, L. Gossec, et al .......................... 1025

Letters
A False-positive Antineutrophil Cytoplasmic Antibody Proteinase 3 Test in a Patient with Pulmonary-renal Syndrome

Correction
Report from the OMERACT Hand OA Special Interest Group: Advances and Future Research Priorities

Meetings in Rheumatology ............................................ x